Tryptamines

"Tryptamines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Decarboxylated monoamine derivatives of TRYPTOPHAN.

Descriptor ID	D014363
MeSH Number(s)	D02.092.211.215.801 D03.633.100.473.914
Concept/Terms	Tryptamines Tryptamines Indolylethylamines Triptans Triptans

Below are MeSH descriptors whose meaning is more general than "Tryptamines".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amines [D02.092]
Biogenic Amines [D02.092.211]
Biogenic Monoamines [D02.092.211.215]
Tryptamines [D02.092.211.215.801]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Indoles [D03.633.100.473]
Tryptamines [D03.633.100.473.914]

Below are MeSH descriptors whose meaning is more specific than "Tryptamines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tryptamines" by people in this website by year, and whether "Tryptamines" was a major or minor topic of these publications.

Bar chart showing 80 publications over 21 distinct years, with a maximum of 9 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	8	8
2003	0	3	3
2004	1	5	6
2005	1	2	3
2006	2	1	3
2007	6	2	8
2008	5	2	7
2009	5	2	7
2010	6	3	9
2011	2	0	2
2012	1	2	3
2013	4	0	4
2014	3	0	3
2016	1	0	1
2017	1	0	1
2018	1	1	2
2019	1	3	4
2020	1	1	2
2021	0	1	1
2022	1	1	2
2023	0	1	1

Below are the most recent publications written about "Tryptamines" by people in Profiles.

Chiang CC, Fang X, Horvath Z, Cadiou F, Urani A, Poh W, Narimatsu H, Cheng Y, Dodick DW. Simultaneous Comparisons of 25 Acute Migraine Medications Based on 10 Million Users' Self-Reported Records From a Smartphone Application. Neurology. 2023 Dec 12; 101(24):e2560-e2570.

View in: PubMed
Cowan RP, Marmura MJ, Diener HC, Starling AJ, Schim J, Hirman J, Brevig T, Cady R. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study. J Headache Pain. 2022 Sep 06; 23(1):115.

View in: PubMed
Lipton RB, Singh RBH, Revicki DA, Zhao S, Shewale AR, Lateiner JE, Dodick DW. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain. 2022 Apr 25; 23(1):50.

View in: PubMed
Nahas SJ, Hindiyeh N, Friedman DI, Elbuluk N, Kellerman DJ, Foreman PK, Schmidt P. Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine. J Headache Pain. 2021 May 17; 22(1):37.

View in: PubMed
Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busard? FP, Huestis MA. Toxicology and Analysis of Psychoactive Tryptamines. Int J Mol Sci. 2020 Dec 04; 21(23).

View in: PubMed
Iljazi A, Chua A, Rich-Fiondella R, Veronesi M, Melo-Carrillo A, Ashina S, Burstein R, Grosberg B. Unrecognized challenges of treating status migrainosus: An observational study. Cephalalgia. 2020 07; 40(8):818-827.

View in: PubMed
Tepper SJ. Acute Treatment of Migraine. Neurol Clin. 2019 11; 37(4):727-742.

View in: PubMed
Mathew PG, Klein BC. Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk. Headache. 2019 09; 59(8):1421-1426.

View in: PubMed
Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019 05 14; 92(20):e2309-e2320.

View in: PubMed
Tepper SJ, Dodick DW, Schmidt PC, Kellerman DJ. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches. Headache. 2019 04; 59(4):509-517.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement